AnaptysBio Inc (NASDAQ: ANAB) on Monday, plunged -8.03% from the previous trading day, before settling in for the closing price of $21.68. Within the past 52 weeks, ANAB’s price has moved between $13.36 and $41.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 172.96% annually for the last half of the decade. The company achieved an average annual earnings per share of -8.60%. With a float of $25.82 million, this company’s outstanding shares have now reached $26.60 million.
In an organization with 117 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.14%, operating margin of -532.89%, and the pretax margin is -558.23%.
AnaptysBio Inc (ANAB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of AnaptysBio Inc is 14.49%, while institutional ownership is 87.81%. The most recent insider transaction that took place on Sep 23 ’24, was worth 58,005. In this transaction Chief Medical Officer of this company sold 1,500 shares at a rate of $38.67, taking the stock ownership to the 15,398 shares. Before that another transaction happened on Sep 23 ’24, when Company’s Officer proposed sale 1,500 for $38.67, making the entire transaction worth $58,005.
AnaptysBio Inc (ANAB) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.41 earnings per share (EPS) for the period topping the consensus outlook (set at -1.79) by 0.38. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.60% per share during the next fiscal year.
AnaptysBio Inc (NASDAQ: ANAB) Trading Performance Indicators
AnaptysBio Inc (ANAB) is currently performing well based on its current performance indicators. A quick ratio of 9.09 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.34, a number that is poised to hit -1.65 in the next quarter and is forecasted to reach -6.75 in one year’s time.
Technical Analysis of AnaptysBio Inc (ANAB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.11 million. That was better than the volume of 0.35 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 4.14%. Additionally, its Average True Range was 2.37.
During the past 100 days, AnaptysBio Inc’s (ANAB) raw stochastic average was set at 1.20%, which indicates a significant decrease from 1.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 137.00% in the past 14 days, which was higher than the 76.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.92, while its 200-day Moving Average is $27.97. However, in the short run, AnaptysBio Inc’s stock first resistance to watch stands at $21.09. Second resistance stands at $22.25. The third major resistance level sits at $22.95. If the price goes on to break the first support level at $19.23, it is likely to go to the next support level at $18.53. The third support level lies at $17.37 if the price breaches the second support level.
AnaptysBio Inc (NASDAQ: ANAB) Key Stats
Market capitalization of the company is 603.57 million based on 27,434K outstanding shares. Right now, sales total 17,160 K and income totals -163,620 K. The company made 10,970 K in profit during its latest quarter, and -46,660 K in sales during its previous quarter.
